Table 3.
Most frequently occurring treatment-related adverse events for all dose combinations
| DPZ | EVP-6124 | N∗ | Somnolence | Dry mouth | Dizziness | Headache | Disturbance in attention | Gait disturbance |
|---|---|---|---|---|---|---|---|---|
| Placebo | Placebo | 35 | 22 (62.9%) | 25 (71.4%) | 19 (54.3%) | 4 (11.4%) | - | 4 (11.4%) |
| Placebo | 0.3 mg | 12 | 6 (50.0%) | 8 (66.7%) | 6 (50.0%) | 1 (8.3%) | 2 (16.7%) | 1 (8.3%) |
| Placebo | 1 mg | 11 | 5 (45.5%) | 8 (72.2%) | 3 (27.3%) | 3 (27.3%) | 2 (18.2%) | 1 (9.1%) |
| Placebo | 2 mg | 12 | 8 (66.7%) | 10 (83.3%) | 4 (33.3%) | - | 1 (8.3%) | 1 (8.3%) |
| Placebo | 4 mg | 12 | 7 (58.3%) | 10 (83.3%) | 5 (41.7%) | 1 (8.3%) | 2 (16.7%) | 3 (25.0%) |
| 2.5 mg | Placebo | 11 | 7 (63.6%) | 6 (54.4%) | 6 (54.4%) | 1 (9.1%) | - | - |
| 5.0 mg | Placebo | 10 | 6 (60.0%) | 6 (60.0%) | 6 (60.0%) | 1 (10.0%) | 1 (10.0%) | - |
| 2.5 mg | 0.3 mg | 11 | 9 (81.8%) | 5 (45.5%) | 6 (54.5%) | 2 (18.2%) | 2 (18.2%) | 1 (9.1%) |
| 2.5 mg | 1 mg | 11 | 9 (81.1%) | 9 (81.1%) | 6 (54.5%) | 3 (27.3%) | 1 (9.1%) | - |
| 2.5 mg | 2 mg | 12 | 11 (91.7%) | 7 (58.3%) | 5 (41.7%) | 4 (33.3%) | 1 (8.3%) | 2 (16.7%) |
| 5.0 mg | 0.3 mg | 11 | 6 (54.5%) | 4 (36.4%) | 5 (45.5%) | - | - | - |
| 5.0 mg | 1 mg | 11 | 8 (72.7%) | 5 (45.5%) | 6 (54.5%) | 1 (9.1%) | 1 (9.1%) | - |
| 5.0 mg | 2 mg | 11 | 8 (72.7%) | 6 (54.5%) | 7 (63.6%) | 1 (9.1%) | 2 (18.2%) | - |
| All | 37 | 31 (83.3%) | 32 (86.5%) | 32 (86.5%) | 11 (29.7%) | 12 (32.4%) | 11 (29.7%) |
Abbreviation: DPZ = donepezil.
∗
All subjects received scopolamine 0.3 mg i.v. on each occasion.